Skip Navigation LinksHome > October 2013 - Volume 61 - Issue 7 > A Postmarketing Surveillance Study on Erbitux (Cetuximab) in...
Journal of Investigative Medicine:
doi: 10.231/JIM.0b013e3182a6799d
Original Articles

A Postmarketing Surveillance Study on Erbitux (Cetuximab) in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-Containing Treatment

Huang, Wen-Tsung*; Chen, Hong-Hwa; Yeh, Chung-Hung; Lu, Yin-Che§; Hwang, Wei-Shou; Huang, Jen-Seng; Chen, Chou-Pin**; Lin, Peng-Chan††; Uen, Wu-Ching‡‡; Lee, Yang-Cheng§§; Wang, Hwei-Ming**; Wu, Hong-Cheng¶¶; Chen, Jinn-Shiun***; Kao, Ruey-Ho†††; Huang, Chi-Chou‡‡‡; Jeng, Hao-Hsuan§§§; Lin, Chia-Jung§§§; Hsieh, Ruey-Kuen MD¶¶¶

Collapse Box

Abstract

Objective

This postmarketing surveillance study evaluated the safety and efficacy of cetuximab therapy in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) in Taiwan.

Methods

Patients with EGFR-expressing mCRC who had failed prior irinotecan-based chemotherapy and were receiving cetuximab therapy were monitored for treatment efficacy and safety from the time of first infusion until 28 days after the last infusion regardless of the reasons fordiscontinuation. The study followed 269 patients for approximately 2years.

Results

No unexpected adverse events associated with cetuximab therapy were reported, and most events were grade 1 or 2. The most common drug-related adverse events of any grade were rash (21.6%) and dermatitis acneiform (4.8%). Reported grade 3/4 events were rash (4.5%), dermatitis acneiform (0.4%), and diarrhea (0.4%). Cetuximab treatment for patients receiving second-/third-line (177 patients) or above therapy (92 patients) was associated with a median progression-free survival time of 3.37 and 3.90 months, respectively, and a median overall survival time of 17.6 and 21.1 months, respectively. The response rates for the second-/third-line treatment and fourth-line or above cetuximab treatment groups were similar (21.5% vs 17.4%; P = 0.428).

Conclusion

Cetuximab showed no unexpected safety findings and was efficacious in treating patients with EGFR-expressing mCRC in community practice in Taiwan.

Copyright © 2013 by The American Federation for Medical Research

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.